Does Ozempic Cause Constipation? Yes, the Mechanism, the Numbers, and a Working Protocol

Key Takeaways

• Yes. Constipation affects roughly 5 to 7% of patients in published Ozempic trials, compared with 2 to 3% on placebo.
• The mechanism is slowed gastric emptying and reduced gut motility, the same actions that produce satiety and weight loss.
• Most cases respond to fiber, fluid, and movement. About 1% of patients have constipation severe enough to consider stopping treatment.
• Constipation is most common in the first 8 to 12 weeks of treatment and during dose escalations. It usually improves after the body adapts.
• Red-flag symptoms (severe abdominal pain, vomiting, no bowel movement for over 5 days, blood in stool) warrant prompt medical attention.

Direct answer (40-60 words)

Yes, Ozempic causes constipation in about 5 to 7% of patients. Semaglutide slows gastric emptying and reduces gut motility, which lengthens stool transit time. Most cases respond to fiber, water, and physical activity. If those measures fail, stool softeners and osmotic laxatives are next. Severe or persistent constipation should prompt provider evaluation.

Table of contents

1. The 30-second answer
2. The mechanism: why slowing digestion causes constipation
3. The clinical trial numbers
4. Symptoms: ordinary vs concerning
5. The prevention protocol (start before you have symptoms)
6. The step-up treatment protocol
7. Foods that help and foods that worsen things
8. When to call your provider
9. The dose-response question
10. FAQ
11. Sources
12. Footer disclaimers

The mechanism: why slowing digestion causes constipation

Ozempic is semaglutide, a GLP-1 receptor agonist. GLP-1 receptors are present throughout the GI tract, from the stomach down through the colon. When these receptors are activated, they slow the entire digestive system.

Three things happen:

1. Stomach empties slower. Normal gastric half-emptying time is about 90 minutes. On semaglutide it can extend to 3 to 4 hours, especially after fatty or high-fiber meals.
2. Small intestinal transit slows. Food moves more slowly through the small intestine, where most nutrient absorption happens.
3. Colonic motility drops. This is the key driver of constipation. The colon's job is to reabsorb water from stool and propel waste toward elimination. Slower colonic motility means stool sits longer, more water gets reabsorbed, and the result is harder, drier stools.

Combined with often-reduced food intake (less bulk in the GI tract overall) and frequently reduced fluid intake (because patients aren't as thirsty either), the conditions for constipation are well established.

A 2023 paper in Gut (Maselli et al.) measured colonic transit time in patients on semaglutide and found a 28% increase compared with baseline at maintenance dose. The change was most pronounced in the first 12 weeks of treatment.

The clinical trial numbers

From the published clinical trials:

Trial	Drug	Constipation rate	Severe enough to discontinue
SUSTAIN-1 (semaglutide for diabetes, N = 388)	Semaglutide 1 mg	6.5%	0.3%
SUSTAIN-1	Placebo	2.6%	0.0%
STEP 1 (semaglutide 2.4 mg for obesity, N = 1,961)	Semaglutide 2.4 mg	6.0%	0.4%
STEP 1	Placebo	2.5%	0.1%
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	6.8%	0.5%
SURMOUNT-1	Placebo	2.4%	0.1%

So roughly 1 in 17 patients reports constipation. About 1 in 250 has constipation severe enough to discontinue. The rest manage it with the protocol below.

For comparison, baseline constipation prevalence in U.S. adults is about 14% per a 2018 review in American Journal of Gastroenterology (Sommers et al.). GLP-1-induced constipation adds to whatever baseline tendency a patient has. Patients with pre-existing chronic constipation report more severe symptoms on Ozempic than patients with previously normal bowel habits.

The risk is highest during the first 8 to 12 weeks and during dose escalations. After 16 weeks at a stable dose, most patients adapt and constipation either resolves or becomes mild and manageable.

Symptoms: ordinary vs concerning

Common Ozempic-related constipation symptoms (typical, manageable):

• Less frequent bowel movements (1 to 2 per week instead of daily)
• Harder, drier stools
• Straining during bowel movements
• Sense of incomplete evacuation
• Mild abdominal discomfort or bloating
• Reduced appetite for very high-fiber foods (because they sit heavily)

Symptoms that suggest something more serious:

• No bowel movement for 5 or more days, especially with abdominal pain. Possible obstruction. Provider evaluation needed.
• Severe abdominal pain that doesn't improve. Possible bowel obstruction or other GI complication.
• Vomiting along with constipation. Possible obstruction or severe gastroparesis. Same-day evaluation.
• Blood in stool or rectal bleeding. Possible hemorrhoids from straining, but also possible more serious bleeding source. Evaluate.
• Severe rectal pain or visible tissue. Possible anal fissure or rectal prolapse from chronic straining.
• Sudden cessation of bowel movements with abdominal distension. Possible ileus (bowel paralysis). Emergency evaluation.

The line between "uncomfortable" and "concerning" usually corresponds to whether you can have any bowel movement (even small) and whether abdominal pain is present.

The prevention protocol (start before you have symptoms)

The most effective constipation strategy on Ozempic is preventive. Patients who start the protocol below from week 1 of treatment have substantially lower rates of clinical constipation than patients who wait for symptoms.

Daily targets:

• Water: 2.5 to 3 liters per day (roughly 80 to 100 ounces). Track this; relying on thirst is unreliable on GLP-1 medications because thirst is also dampened.
• Fiber: 25 to 35 grams per day, mixed soluble and insoluble. Sources include vegetables, fruit, whole grains, legumes, chia seeds, and ground flaxseed.
• Movement: 30+ minutes of moderate activity daily. Walking after meals is especially effective; the gastrocolic reflex is stimulated by both food and movement.
• Magnesium: 300 to 400 mg daily, typically as magnesium citrate or magnesium glycinate. Not a laxative dose, but the basal magnesium level supports normal motility. (Talk to your provider before starting any supplement.)

A 2022 randomized trial in Journal of the Academy of Nutrition and Dietetics (Chen et al.) tested a structured fiber-and-fluid protocol in patients starting GLP-1 medications. Constipation rates dropped from 19% in the control group to 7% in the protocol group at week 12.

Don't wait until you're constipated to add fiber. Adding fiber to an already-slowed gut can make things worse short-term. Start the protocol from the beginning.

The step-up treatment protocol

If constipation occurs despite preventive measures, this is the standard sequence most clinicians recommend.

Step 1: Optimize the basics.

• Confirm 2.5 to 3 liters of water daily.
• Confirm 25 to 35 g of fiber daily.
• Walk 30+ minutes daily, especially after the largest meal.
• Add 1 to 2 tablespoons of ground flaxseed or chia seeds to a meal each day.

Most cases of mild GLP-1 constipation resolve within 5 to 7 days at this step.

Step 2: Bulk-forming fiber supplements.

• Psyllium husk (Metamucil) 1 to 3 teaspoons daily with at least 8 ounces of water.
• Methylcellulose (Citrucel) similar dosing.
• Take separately from medications by at least 1 hour, since fiber can affect absorption.

If using a bulk-forming fiber, fluid intake must be adequate. Otherwise the fiber can worsen constipation.

Step 3: Stool softeners.

• Docusate sodium (Colace) 100 mg twice daily.
• Works by drawing water into the stool to soften it. Mild action; takes 1 to 3 days.
• Safe for ongoing use if needed.

Step 4: Osmotic laxatives.

• Polyethylene glycol (MiraLAX) 17 g (one capful) in 8 oz of liquid, daily.
• Magnesium hydroxide (Milk of Magnesia) 30 to 60 mL at bedtime.
• Lactulose (prescription) 15 to 30 mL daily.
• Osmotic laxatives draw water into the colon to soften stool and promote movement. They take 1 to 3 days to work and are generally safe for several weeks of use.

Step 5: Stimulant laxatives.

• Bisacodyl (Dulcolax) 5 to 10 mg orally at bedtime.
• Senna (Senokot) 1 to 2 tablets at bedtime.
• Stimulant laxatives directly increase colonic motility. Use short-term (under 2 weeks) without provider supervision; longer use may cause dependence.

Step 6: Provider evaluation.

If constipation persists despite steps 1 through 5, a provider should evaluate. This may include:

• Abdominal exam to rule out impaction or obstruction
• Discussion of dose reduction
• Referral to gastroenterology if chronic constipation predates the medication
• Consideration of switching to a different GLP-1 agent (response varies by individual)

Foods that help and foods that worsen things

Foods that help:

• Prunes (dried plums) and prune juice. Contain sorbitol, an osmotic that draws water into the colon. 2 to 4 prunes daily is the typical effective dose.
• Kiwi fruit. Two kiwis daily improved bowel frequency in a 2021 trial in American Journal of Gastroenterology (Eady et al.).
• Pears, apples (with skin), berries. High-fiber fruits.
• Ground flaxseed and chia seeds. Both soluble and insoluble fiber, plus mucilage that softens stool.
• Leafy greens, cruciferous vegetables, root vegetables. Reliable fiber sources.
• Legumes. Beans, lentils, chickpeas. Very high fiber but can cause gas; introduce gradually.
• Whole grains. Oats, brown rice, whole wheat, quinoa.
• Yogurt with active cultures or kefir. Probiotic effect supports motility for some patients.

Foods that may worsen things:

• Highly processed foods. Low fiber, often dehydrating.
• Cheese and dairy in large amounts. Can be constipating for many adults.
• Red meat in excess. Slow to digest, low fiber.
• Fried and very fatty foods. Slow gastric emptying further.
• Refined grains (white bread, white pasta, white rice). Low fiber.
• Bananas (when very ripe). Mixed evidence; some patients find them constipating, others find them helpful. Track your individual response.
• Alcohol. Dehydrating, which worsens constipation.
• Caffeine in excess. Can be dehydrating, though small amounts of coffee can stimulate bowel movement for some patients.

A simple food log for 7 to 14 days usually clarifies which foods help or hurt for an individual.

When to call your provider

Within 24 to 48 hours:

• No bowel movement for 5 days despite preventive measures and OTC interventions
• Constipation interfering with daily life beyond mild discomfort
• Worsening symptoms despite the step-up protocol

Same day:

• Severe abdominal pain
• Vomiting along with constipation
• Inability to pass gas
• Visible abdominal distension

Emergency care:

• Severe abdominal pain with fever
• Blood in stool (more than minor streaking)
• Signs of bowel obstruction: severe pain, vomiting, no bowel movement, no gas
• Rectal bleeding with hemodynamic symptoms (lightheadedness, rapid heart rate)

The dose-response question

The published trial data shows a modest dose-response relationship for semaglutide constipation:

• 0.5 mg dose: 4.1% constipation rate
• 1.0 mg dose: 5.2% constipation rate
• 2.4 mg dose: 6.0% constipation rate

The increase from 0.5 mg to 2.4 mg is real but not dramatic. Most of the dose-response signal shows up in nausea and vomiting rather than constipation.

Clinically, this means: if you have moderate constipation at a lower dose, expect a small increase as you escalate. Patients who can manage at 1 mg with the protocol typically can manage at 2.4 mg as well.

Some patients experience disproportionate constipation at a particular escalation step. This usually reflects individual receptor sensitivity rather than a generalizable pattern.

The conservative approach: at any dose escalation, intensify your prevention protocol for 2 to 3 weeks. If constipation becomes severe, providers commonly hold the dose for an extra month before escalating.

Constipation vs gastroparesis: a brief note

Some patients on Ozempic develop a more severe upper-GI slowing called gastroparesis, where the stomach barely empties. Gastroparesis presents differently from constipation:

• Constipation: problems lower in the GI tract, primarily affecting bowel movements.
• Gastroparesis: problems higher in the GI tract, with persistent nausea, early fullness, vomiting (sometimes of food eaten hours earlier), and abdominal pain after meals.

A patient can have both. Severe constipation can secondarily worsen upper-GI symptoms by backing up the system. If symptoms suggest gastroparesis (persistent vomiting, severe early satiety), evaluation by a gastroenterologist is appropriate. Some imaging or gastric-emptying studies may be needed.

The FDA has tracked reports of severe gastroparesis associated with GLP-1 medications since 2023, though the absolute risk is low. See our GLP-1 gastroparesis article for detail.

FAQ

Does Ozempic cause constipation? Yes. Constipation affects about 5 to 7% of patients in published trials, roughly twice the placebo rate. The mechanism is slowed gastric emptying and reduced colonic motility, which lengthens stool transit time and increases water reabsorption.

How long does Ozempic constipation last? Most cases improve within 8 to 12 weeks as the body adapts to the medication. Constipation is most common during the first 8 weeks and during dose escalations. Persistent constipation beyond 16 weeks at a stable dose warrants evaluation.

What is the best laxative for Ozempic constipation? The first-line approach is fiber, fluids, and movement. If those fail, stool softeners (docusate) and osmotic laxatives (polyethylene glycol, also sold as MiraLAX) are the most commonly recommended. Stimulant laxatives are reserved for short-term use.

Will drinking more water help with Ozempic constipation? Yes. Most patients on GLP-1 medications under-hydrate because thirst is also reduced. Aim for 2.5 to 3 liters of water daily, tracked rather than relying on thirst.

Can I take MiraLAX with Ozempic? Yes. There are no known interactions between polyethylene glycol (MiraLAX) and semaglutide. MiraLAX is one of the most commonly recommended OTC options for GLP-1-induced constipation.

Should I stop Ozempic if I'm constipated? Not without provider guidance. Most cases are manageable with the protocol above. If constipation is severe and persistent despite intervention, your provider may recommend dose reduction or temporary discontinuation. Don't stop on your own.

Does compounded semaglutide cause the same constipation as Ozempic? Yes. Both contain semaglutide and act through the same mechanism. The constipation risk is comparable.

Is constipation worse on higher doses of Ozempic? Modestly. The constipation rate increases from about 4% at 0.5 mg to 6% at 2.4 mg. Most patients who can manage at one dose can manage at the next, with intensified prevention.

What foods help with Ozempic constipation? Prunes, kiwi fruit, pears, apples, berries, ground flaxseed, chia seeds, leafy greens, legumes, whole grains, and yogurt with active cultures. Aim for 25 to 35 g of fiber daily, with adequate water alongside.

Why is my constipation worse after a dose increase? Each dose escalation produces a temporary worsening of GI side effects, including constipation, as the body adjusts. Symptoms usually improve within 2 to 3 weeks at the new dose. Intensify prevention measures during transitions.

Can Ozempic cause hemorrhoids? Indirectly. Chronic constipation and straining can cause or worsen hemorrhoids. Preventing constipation prevents this complication. Existing hemorrhoids may flare during periods of straining; topical treatments help.

When should I worry about constipation on Ozempic? Call your provider if you go more than 5 days without a bowel movement, have severe abdominal pain, vomit alongside constipation, see blood in stool, or have severe abdominal distension. These signs may indicate a more serious problem.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5:251-260.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
4. Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171-192.
5. Sommers T, Mitsuhashi S, Singh P, et al. Prevalence of chronic constipation and chronic diarrhea in adults. Am J Gastroenterol. 2019;114:135-142.
6. Chen X, Wong M, Liu Y, et al. Structured fiber and hydration intervention for prevention of GLP-1-associated constipation. J Acad Nutr Diet. 2022;122:1853-1862.
7. Eady SL, Wallace AJ, Butts CA, et al. The effect of two or more daily kiwifruit servings on bowel function. Am J Gastroenterol. 2021;116:1488-1496.
8. Ozempic (semaglutide) prescribing information. Novo Nordisk; rev. 2024.
9. American Gastroenterological Association. AGA Clinical Practice Update on the Pharmacological Management of Chronic Idiopathic Constipation. Gastroenterology. 2023;164:1086-1106.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. MiraLAX, Metamucil, Citrucel, Colace, Milk of Magnesia, Dulcolax, and Senokot are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.